Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with refractory pancreatic cancer (TRIPLE-R) - Concepedia

Concepedia

Publication | Open Access

Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with refractory pancreatic cancer (TRIPLE-R)

DOI Full Paper Access

30

Citations

23

References

2022

Year

Inna M. Chen, Marco Donia, Christopher A. Chamberlain, Agnete W.P. Jensen, Arianna Draghi, Susann Theile, Kasper Madsen, Jane Preuss Hasselby, Anders Toxværd, Estrid Høgdall,

European Journal of Cancer

Abstract

The combination of ipilimumab, nivolumab, tocilizumab, and SBRT in patients with PC did not meet the prespecified criteria for expansion for full accrual.

References

	Year	Citations

Page 1